Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGNA: Pembrolizumab Alone or with Chemotherapy in Advanced Non-Squamous NSCLC
NCT03793179Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2019
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival. Started Apr 2019; status: active, not recruiting.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03793179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793179.